Vertex Pharmaceuticals (VRTX) valuation
Vertex Pharmaceuticals P/E ratio history
Vertex Pharmaceuticals trades at 32.6 times its earnings over the last twelve months and 28.6 times the earnings analysts expect over the next twelve. At its last 8 fiscal year ends its P/E ranged from 20.5 (year to Dec 2018) to 144.1 (year to Dec 2017), with a median of 26.8.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $453.36 | $15.32 | 29.6 | 22.8 |
| Dec 31, 2024 | $402.70 | -$2.08 | n/m | — |
| Dec 31, 2023 | $406.89 | $13.89 | 29.3 | 25.3 |
| Dec 31, 2022 | $288.78 | $12.82 | 22.5 | 19.1 |
| Dec 31, 2021 | $219.60 | $9.01 | 24.4 | 16.5 |
| Dec 31, 2020 | $236.34 | $10.30 | 23.0 | — |
| Dec 31, 2019 | $218.95 | $4.51 | 48.6 | — |
| Dec 31, 2018 | $165.71 | $8.08 | 20.5 | — |
| Dec 31, 2017 | $149.86 | $1.04 | 144.1 | — |
| Dec 31, 2016 | $73.67 | -$0.46 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Vertex Pharmaceuticals valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Vertex PharmaceuticalsVRTX | $142B | 32.6 | 28.6 | 11.3 |
| RegeneronREGN | $97.3B | 23.0 | 17.2 | 6.3 |
| Gilead SciencesGILD | $212B | — | 35.9 | 6.8 |
| ModernaMRNA | $88.0B | — | — | 39.5 |
| AmgenAMGN | $252B | 29.0 | 19.6 | 6.6 |
| AbbVieABBV | $521B | 83.3 | 18.9 | 8.1 |
| BiogenBIIB | $37.5B | 109.3 | 16.6 | 3.6 |
| CibusCBRS | $24.7B | — | — | — |
| InsmedINSM | $24.6B | — | — | 16.2 |
| Peer median | 56.1 | 18.9 | 6.8 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: VRTX financials · VRTX returns
No forecast, no recommendation. This page describes Vertex Pharmaceuticals from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.